Zymeworks Inc.

Zymeworks Inc., with its slogan "Developing novel medicines for patients with difficult-to-treat cancers and other serious diseases,” is a pioneering player in the biotechnology and health and wellness industries. Founded in 2003 and headquartered in Canada, the company is focused on advancing a portfolio of differentiated biotherapeutics aimed at improving care standards for challenging cancer and autoimmune diseases.

Leveraging proprietary antibody engineering platforms, Zymeworks Inc. has built a diverse pipeline incorporating multispecific antibodies and antibody-drug conjugates. Notably, their partnered programs include Ziihera® (zanidatamab-hrii), showcasing their commitment to innovative solutions.

The company's robust R&D capabilities, in conjunction with strategic partnerships, drive the development of next-generation antibody therapeutics addressing significant unmet medical needs. Their latest funding, a $250.00M Post IPO Debt investment secured in March 2026 with Royalty Pharma, highlights investor confidence in their strategic direction and potential for impactful growth.